CSIMarket Company Name, Ticker, Suppliers, else..
 
Promis Neurosciences inc   (NASDAQ: PMN)
 
Price: $11.5700 $-1.37 -10.587%
Day's High: $13.0600004196167 Week Perf: -17.42 %
Day's Low: $ 11.29 30 Day Perf: -24.67 %
Volume (M): 52,695 52 Wk High: $ 27.40
Volume (M$): $ 0 52 Wk Avg: $12.27
Open: $12.65 52 Wk Low: $6.27



 Market Capitalization (Millions $) 106
 Shares Outstanding (Millions) 9
 Employees 11
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -42
 Cash Flow (TTM) (Millions $) 59
 Capital Exp. (TTM) (Millions $) 0

Business Description


Promis Neurosciences Inc is a pharmaceutical company that focuses on developing and commercializing innovative therapies for the treatment of neurodegenerative diseases. The company's main mission is to discover, develop, and deliver therapeutics that target the underlying causes and progression of these diseases. Promis Neurosciences is known for its expertise in neurodegeneration and its ability to identify novel drug candidates that have the potential to improve patients' lives. The company is committed to advancing its pipeline of drugs and is dedicated to making a significant impact in the field of neurology.


   Company Address: Suite 200, 1920 Yonge Street Toronto 0 ON
   Company Phone Number: 847-6898   Stock Exchange / Ticker: NASDAQ PMN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BHVN   -5.04%    
CRNX        0.11% 
MTVA        2.52% 
PTIX        2.38% 
SPRB   -8.99%    
TAOX        9.56% 
• View Complete Report
   



Announcement

ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimers Trial o...

Published Wed, Sep 3 2025 12:05 PM UTC

Advancements in Alzheimer s Therapy: ProMIS Neurosciences PMN310 Progresses to Final Dose Escalation in Phase 1b Clinical Trial Alzheimer s disease (AD), the most prevalent form of dementia, continues to be a critical public health challenge worldwide, with limited therapeutic options. Emerging therapies targeting amyloid-beta aggregates hold potential for altering the di...
Announcement

ProMIS Neurosciences Pioneering Alzheimer’s Treatments with Accelerated FDA Designations and Promising Preclinical ...

Published Wed, Aug 13 2025 11:55 AM UTC

In a monumental stride towards addressing one of the most pressing healthcare challenges of our time, ProMIS Neurosciences has made significant headway with its innovative approach to Alzheimer’s disease and other neurodegenerative disorders. As substantiated by various recent announcements, ProMIS is not only advancing its pipeline but also capturing attention on the glob...
Announcement

“Unlocking Hope ProMIS Neurosciences’ Strategic Advances in the Fight Against Neurodegenerative Diseases”,

Published Mon, Mar 31 2025 12:40 PM UTC

Unlocking Hope: ProMIS Neurosciences’ Strategic Advances in the Fight Against Neurodegenerative Diseases In an era marked by advancing scientific frontiers, ProMIS Neurosciences Inc. has consistently fortified its position as a pioneering entity in the realm of biotechnology. In light of recent developments, the company has demonstrated not only fiscal resilience but also ...
Announcement

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Disea...

Published Mon, Mar 24 2025 11:21 AM UTC

ProMIS Neurosciences: Promising Advances in Antibody Therapeutics Amidst Competitive Revenue ChallengesIn a pivotal moment for the field of neurodegenerative disease research, ProMIS Neurosciences has recently showcased groundbreaking preclinical data regarding its antibody therapeutics and vaccines at the prestigious Alzheimer s Disease/Parkinson s Disease 2025 Internation...
Announcement

ProMIS Neurosciences Pioneering Antibody Therapeutics for Neurodegenerative Diseases

Published Mon, Jan 13 2025 3:35 PM UTC

Neurodegenerative diseases such as Alzheimer s disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) pose significant challenges in both clinical treatment and research. As these diseases progress, the toxic accumulation of misfolded proteins contributes to neuronal degeneration and loss of function. ProMIS Neurosciences Inc. a clinical-stage ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 2.14
PEG (TTM) -

Financial Strength Current
Quick Ratio 7.41
Working Capital Ratio 7.9
Leverage Ratio (MRQ) 0.15
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -14.62 $
Revenues (TTM) -
Cash Flow (TTM) 6.49 $
Cash 5.85 $
Book Value 5.4 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -3,838,931
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.